世界の心臓再同期療法除細動器(CRT-D)市場:医療機器パイプライン分析2016

◆英語タイトル:Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) - Medical Devices Pipeline Assessment, 2016
◆商品コード:GDME0192EPD
◆発行会社(調査会社):GlobalData
◆発行日:2016年6月1日
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥555,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD7,500 ⇒換算¥832,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、心臓再同期療法除細動器(CRT-D)のグローバル製品パイプライン動向について調査・分析し、以下の構成でお届けいたします。
・心臓再同期療法除細動器(CRT-D)の概要
・心臓再同期療法除細動器(CRT-D)の開発動向:開発段階別分析
・心臓再同期療法除細動器(CRT-D)の開発動向:セグメント別分析
・心臓再同期療法除細動器(CRT-D)の開発動向:領域別分析
・心臓再同期療法除細動器(CRT-D)の開発動向:規制Path別分析
・心臓再同期療法除細動器(CRT-D)の開発動向:承認日(推定)別分析
・企業別心臓再同期療法除細動器(CRT-D)の開発動向(パイプライン製品、進行中の治験)
・心臓再同期療法除細動器(CRT-D)の最近動向
【レポートの概要】

Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Medical Devices Pipeline Assessment, 2016

Summary

GlobalData’s Medical Devices sector report, “Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Medical Devices Pipeline Assessment, 2016″ provides an overview of Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) Overview 6
3 Products under Development 7
3.1 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Stage of Development 7
3.2 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Segment 8
3.3 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Territory 9
3.4 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Regulatory Path 10
3.5 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Estimated Approval Date 11
3.6 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Ongoing Clinical Trials 12
4 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products under Development by Companies 13
4.1 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) Companies – Pipeline Products by Stage of Development 13
4.2 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Stage of Development 14
5 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) Companies and Product Overview 15
5.1 Boston Scientific Corporation Company Overview 15
5.1.1 Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 15
5.2 John Hopkins University Company Overview 20
5.2.1 John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 20
5.3 LivaNova PLC Company Overview 22
5.3.1 LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 22
5.4 Medtronic plc Company Overview 28
5.4.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 28
5.5 Sorin Group Italia S.r.l Company Overview 30
5.5.1 Sorin Group Italia S.r.l Pipeline Products & Ongoing Clinical Trials Overview 30
5.6 St. Jude Medical, Inc. Company Overview 33
5.6.1 St. Jude Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 33
5.7 TransWorld Med Corporation Company Overview 37
5.7.1 TransWorld Med Corporation Pipeline Products & Ongoing Clinical Trials Overview 37
6 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D)- Recent Developments 38
6.1 May 16, 2016: Heart Hospital of Austin First in Texas to Offer MultiPoint Pacing Technology for Heart Failure Patients 38
6.2 May 05, 2016: SonR: 35% Risk Reduction in Heart Failure Hospitalization 38
6.3 May 04, 2016: Overlake Becomes First Hospital in Washington to Offer MultiPoint Pacing Technology for Heart Failure Patients 40
6.4 Apr 27, 2016: Boston Scientific Announces Results For First Quarter 2016 40
6.5 Apr 26, 2016: Allied 100 Acquires Lifeguard Medical Solutions 42
6.6 Apr 18, 2016: St. Jude Medical Announces Launch And First US Implants Of MultiPoint Pacing Technology 42
6.7 Apr 13, 2016: Nihon Kohden Evolves Brand, Website to Meet Needs of Changing Healthcare Environment 43
6.8 Apr 08, 2016: Lankenau Heart Institute at Paoli Hospital has Implanted the Region’s First MRI-Safe Cardiac Resynchronization Defibrillator 44
6.9 Apr 05, 2016: St. Jude Medical Announces MHLW Approval for MRI Conditional Labeling on Quadra Assura CRT-D to Improve Access to Diagnostic Imaging for Heart Failure Patients 44
6.10 Feb 25, 2016: Boston Scientific Announces Changes to Board of Directors 45
6.11 Feb 22, 2016: Medtronic Receives CE Mark for Full Line of Cardiac Resynchronization Therapy-Defibrillators Compatible with MRI Scans 46
6.12 Feb 05, 2016: Medtronic’s Amplia MRI Quad CRT-D SureScan System Receives FDA Approval for Treatment of Heart Failure 47
6.13 Feb 05, 2016: Medtronic’s Compia MRI Quad CRT-D SureScan System Receives FDA Approval For Treatment Of Heart Failure 48
6.14 Feb 04, 2016: Boston Scientific Announces Results for Fourth Quarter and Full Year Ended December 31, 2015 49
6.15 Feb 03, 2016: Nihon Kohden America Receives Great Place to Work Certification 50
6.16 Feb 02, 2016: Mostyn Law wins court order barring Boston Scientific from destroying evidence 50
6.17 Dec 10, 2015: BIOTRONIK Announces Start of New Study Evaluating whether Pacemakers with Closed Loop Stimulation Prevent Reflex Syncope 51
6.18 Dec 02, 2015: St. Jude Medical Announces CE Mark for MRI Compatibility on Quadra Assura CRT-D to Improve Access to Diagnostic Imaging for Heart Failure Patients 51
6.19 Dec 01, 2015: BIOTRONIK Announces Start of Study to Evaluate Benefits of Unique Rate Response Algorithm for Atrial Fibrillation Patients 52
6.20 Oct 28, 2015: Boston Scientific Announces Results For Third Quarter 2015 53
6.21 Aug 25, 2015: BIOTRONIK presents its CRT-Ds Approved for Full-Body MRI Scanning at ESC Congress 2015 54
6.22 Aug 24, 2015: Boston Scientific Announces CE Mark For MRI Compatible Labeling For ICD And CRT-D Systems 54
6.23 Aug 05, 2015: BIOTRONIK Announces Start of First Study to Assess Relevance of Defibrillator Back-Up after CRT-D Replacement 55
6.24 Jul 31, 2015: Consolidated Financial Results for the 1st Quarter of the Fiscal Year Ending March 31, 2016 56
6.25 Jul 24, 2015: ZOLL Equips Toronto 2015 Pan American, Parapan American Games with Defibrillators 57
6.26 Jul 24, 2015: ZOLL Equips Toronto 2015 Pan American, Parapan American Games with Defibrillators 58
6.27 Jul 23, 2015: Boston Scientific Announces Results For Second Quarter 2015 58
6.28 Jul 16, 2015: ZOLL Announces Release of Its CPR Extract Capability 59
6.29 Jul 02, 2015: BIOTRONIK Announces Start of Pioneering BIOWOMEN Study 60
6.30 Jun 22, 2015: Boston Scientific Begins EMBLEM Defibrillator Study In Sudden Cardiac Death 60
6.31 Jun 16, 2015: Hill-Rom Acquires Welch Allyn for USD2.05 Billion 61
7 Appendix 62
7.1 Methodology 62
7.2 About GlobalData 64
7.3 Contact Us 65
7.4 Disclaimer 65

1.1 List of Tables
Table 1: Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) - Pipeline Products by Stage of Development 7
Table 2: Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) - Pipeline Products by Segment 8
Table 3: Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) - Pipeline Products by Territory 9
Table 4: Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) - Pipeline Products by Regulatory Path 10
Table 5: Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) - Pipeline Products by Estimated Approval Date 11
Table 6: Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) - Ongoing Clinical Trials 12
Table 7: Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) Companies - Pipeline Products by Stage of Development 13
Table 8: Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) - Pipeline Products by Stage of Development 14
Table 9: Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 15
Table 10: Autogen X4 CRT-D - Product Status 15
Table 11: Autogen X4 CRT-D - Product Description 16
Table 12: Next Generation Quad Polar CRT-D - Product Status 16
Table 13: Next Generation Quad Polar CRT-D - Product Description 16
Table 14: NG3 Non Quad System - Product Status 17
Table 15: NG3 Non Quad System - Product Description 17
Table 16: Boston Scientific Corporation - Ongoing Clinical Trials Overview 18
Table 17: Autogen X4 CRT-D - Capture Information Via Automatic Threshold Evaluation 19
Table 18: Autogen X4 CRT-D - Sleep-disordered Breathing in Patients with Implanted Cardiac Devices: Validation of the Apneascan Algorithm and Implications for Prognosis 19
Table 19: John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 20
Table 20: Cardiac Arrhythmia Termination Device - Product Status 20
Table 21: Cardiac Arrhythmia Termination Device - Product Description 21
Table 22: LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 22
Table 23: Paradym RF Platform - Product Status 22
Table 24: Paradym RF Platform - Product Description 23
Table 25: PARADYM RF SonR CRT-D - Product Status 23
Table 26: PARADYM RF SonR CRT-D - Product Description 24
Table 27: Platinium Brady - Product Status 24
Table 28: Platinium Brady - Product Description 25
Table 29: Platinium Tachy - Product Status 25
Table 30: Platinium Tachy - Product Description 25
Table 31: LivaNova PLC - Ongoing Clinical Trials Overview 26
Table 32: PARADYM RF SonR CRT-D - Continued Access Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the Paradym RF SonR CRT-D 27
Table 33: PARADYM RF SonR CRT-D - First Implant Of A New-Generation CRT-D Device Designed To Provide Hemodynamic Management Of Heart Failure 27
Table 34: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 28
Table 35: MRI Safe CRT-D - Product Status 28
Table 36: MRI Safe CRT-D - Product Description 29
Table 37: Sorin Group Italia S.r.l Pipeline Products & Ongoing Clinical Trials Overview 30
Table 38: Paradym CRT-D Tri-V Device - Product Status 30
Table 39: Paradym CRT-D Tri-V Device - Product Description 30
Table 40: Sorin Group Italia S.r.l - Ongoing Clinical Trials Overview 31
Table 41: Paradym CRT-D Tri-V Device - SonR FIX Atrial Lead Multi-Centre Clinical Trial 32
Table 42: Paradym CRT-D Tri-V Device - Triple-site Biventricular Stimulation in the Optimization of Cardiac Resynchronization Therapy (CRT) 32
Table 43: St. Jude Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 33
Table 44: Quadra Assura MP CRT-D - Product Status 33
Table 45: Quadra Assura MP CRT-D - Product Description 34
Table 46: St. Jude Medical, Inc. - Ongoing Clinical Trials Overview 35
Table 47: Quadra Assura MP CRT-D - Italian Registry on Multipoint Left Ventricular 36
Table 48: TransWorld Med Corporation Pipeline Products & Ongoing Clinical Trials Overview 37
Table 49: Soul Mate - Defibrillator - Product Status 37
Table 50: Soul Mate - Defibrillator - Product Description 37
Table 51: Glossary 63

1.2 List of Figures
Figure 1: Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) - Pipeline Products by Stage of Development 7
Figure 2: Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) - Pipeline Products by Segment 8
Figure 3: Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) - Pipeline Products by Territory 9
Figure 4: Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) - Pipeline Products by Regulatory Path 10
Figure 5: Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) - Pipeline Products by Estimated Approval Date 11
Figure 6: Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) - Ongoing Clinical Trials 12

【掲載企業】

Boston Scientific Corporation
John Hopkins University
LivaNova PLC
Medtronic plc
Sorin Group Italia S.r.l
St. Jude Medical, Inc.
TransWorld Med Corporation

★調査レポート[世界の心臓再同期療法除細動器(CRT-D)市場:医療機器パイプライン分析2016]販売に関する免責事項
★調査レポート[世界の心臓再同期療法除細動器(CRT-D)市場:医療機器パイプライン分析2016]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆